The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...